vs
Side-by-side financial comparison of INFINITY NATURAL RESOURCES, INC. (INR) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
INFINITY NATURAL RESOURCES, INC. is the larger business by last-quarter revenue ($115.5M vs $103.7M, roughly 1.1× Twist Bioscience Corp). INFINITY NATURAL RESOURCES, INC. runs the higher net margin — 17.3% vs -29.4%, a 46.8% gap on every dollar of revenue.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
INR vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $115.5M | $103.7M |
| Net Profit | $20.0M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | 47.0% | -31.7% |
| Net Margin | 17.3% | -29.4% |
| Revenue YoY | — | 16.9% |
| Net Profit YoY | — | 3.4% |
| EPS (diluted) | $1.33 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $115.5M | $103.7M | ||
| Q3 25 | $78.3M | — | ||
| Q2 25 | $72.5M | — | ||
| Q1 25 | $84.2M | — |
| Q4 25 | $20.0M | $-30.5M | ||
| Q3 25 | $10.4M | — | ||
| Q2 25 | $18.0M | — | ||
| Q1 25 | $-34.6M | — |
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — |
| Q4 25 | 47.0% | -31.7% | ||
| Q3 25 | 30.5% | — | ||
| Q2 25 | 29.9% | — | ||
| Q1 25 | -104.5% | — |
| Q4 25 | 17.3% | -29.4% | ||
| Q3 25 | 13.3% | — | ||
| Q2 25 | 24.8% | — | ||
| Q1 25 | -41.1% | — |
| Q4 25 | $1.33 | $-0.50 | ||
| Q3 25 | $0.65 | — | ||
| Q2 25 | $1.18 | — | ||
| Q1 25 | $-2.27 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.8M | $197.9M |
| Total DebtLower is stronger | $55.0K | — |
| Stockholders' EquityBook value | $307.1M | $456.1M |
| Total Assets | $1.2B | $638.1M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.8M | $197.9M | ||
| Q3 25 | $4.6M | — | ||
| Q2 25 | $6.3M | — | ||
| Q1 25 | $4.9M | — |
| Q4 25 | $55.0K | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $123.0K | — |
| Q4 25 | $307.1M | $456.1M | ||
| Q3 25 | $288.6M | — | ||
| Q2 25 | $10.1M | — | ||
| Q1 25 | $-52.2M | — |
| Q4 25 | $1.2B | $638.1M | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $953.9M | — |
| Q4 25 | 0.00× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $75.1M | $-24.8M |
| Free Cash FlowOCF − Capex | — | $-34.8M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | — | 9.6% |
| Cash ConversionOCF / Net Profit | 3.75× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $75.1M | $-24.8M | ||
| Q3 25 | $42.1M | — | ||
| Q2 25 | $70.4M | — | ||
| Q1 25 | $74.2M | — |
| Q4 25 | — | $-34.8M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — |
| Q4 25 | — | -33.5% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — |
| Q4 25 | — | 9.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — |
| Q4 25 | 3.75× | — | ||
| Q3 25 | 4.04× | — | ||
| Q2 25 | 3.91× | — | ||
| Q1 25 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
INR
| Oil Reserves | $54.0M | 47% |
| Natural Gas Reserves | $46.8M | 41% |
| Natural Gas Liquids Reserves | $14.7M | 13% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
